BLUE BELL, Pa., May 12, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that MDB Capital Group has recognized Inovio with its CLARUS Award, given annually to publicly traded companies possessing market-changing intellectually property (IP) assets. The award was presented at the second annual Bright Lights Conference in New York City, a meeting that provides institutional investors with a venue to discover the largely unrecognized value of intellectual property.
Christopher A. Marlett, CEO of MDB Capital Group, said, "Inovio Pharmaceuticals was the top company in its industry with the highest 'Tech Score' and number of patent grants, and we are honored to recognize their achievements in driving IP as an asset class and the impact they are making on innovation in America."
MDB's "Tech Score" measures the industry impact of a company's patents, as it is an indicator of a company's competitive position. It is based upon an analysis of the citation ratios of a company's patents relative to its peer group.
Inovio's DNA vaccine pipeline and proprietary delivery technology were selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property. Inovio is one of 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by MDB.
Dr. J. Joseph Kim, Inovio's president and CEO, said: "Intellectual property is the lifeblood of medical innovation and Inovio is proud to be recognized for its preeminent patent estate for our pipeline of DNA vaccines and our innovative vaccine delivery technology."
About MDB Capital Group
MDB Capital Group, LLC is an institutional research and investment banking firm focusing exclusively on small and micro-cap companies possessing market changing, disruptive intellectual property. For more information on MDB Capital Group, visit: http://www.mdb.com
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include three separate programs in Phase II clinical studies, including VGX-3100 for treating cervical dysplasia and cancer. Other Inovio clinical programs include those for avian flu (preventive) and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.